p.novotny
TL2 Regular · Prague, CZ
Lifter. Interested in preserving what I spent a decade building while losing fat.
Joined 3 June 2025 · last posted 4d
102Posts here
0Topics
1Solutions
138Likes received
213Likes given
18Badges
115Days visited
1.1kPosts read
Stated areas
Recent activity
Full stream-
[2026 update] Travelling with an injectable: documentation and practicalities Replied, post #106 · Access › International · 24 Jul 2026 · 4 likes Travelling with a prescribed medicine is a documentation question and the requirements are published by the destination rather than the origin.
-
Restarting after a long gap: what the labelling implies Replied, post #37 · Practice › Dosing & titration · 21 Jul 2026 · 3 likes Concentration and dose get conflated constantly in this subcategory. Changing how much diluent you add changes the volume you draw and changes nothing about the dose.
-
Follow-up: How compounding permissions changed when supply normalised Replied, post #24 · Sourcing › Regulatory · 15 Jul 2026 · 0 likes An indication approved for one age range does not extend to another, and paediatric extensions are separate decisions with separate evidence.
-
Follow-up: Signs of dehydration worth acting on Replied, post #25 · Safety › Adverse events · 15 Jul 2026 · 0 likes Severe gastrointestinal events: persistent vomiting, abdominal pain out of proportion, or signs of bowel obstruction warrant urgent evaluation. Mild nausea and…
-
Stepping down deliberately, and how to do it without losing progress — what changed since Replied, post #60 · Practice › Dosing & titration · 13 Jul 2026 · 8 likes When a dose reduction is the correct response to a side effect: if a side effect is dose-dependent (nausea, constipation, injection discomfort), reducing the dose is a…
-
Why retatrutide discussion here is more cautious than elsewhere — one year on Replied, post #57 · Compounds › Retatrutide · 12 Jul 2026 · 2 likes I read post #56 twice before replying, because I had assumed the opposite. On analysis: a chromatographic purity figure for an investigational compound is harder to…
-
Named, unnamed and unspecified impurities as regulatory categories — the long version Replied, post #52 · Analytics › Impurities & related substances · 6 Jul 2026 · 13 likes I read post #50 twice before replying, because I had assumed the opposite. The honest reading of a purity figure: it is an upper bound on how much of what the method…
-
Journal club: orforglipron phase 2 and the non-peptide question Replied, post #111 · Evidence › Journal club · 5 Jul 2026 · 20 likes Coming back to post #109, because the follow-up matters more than the original answer. Practical experience of orforglipron phase 2, offered as one case with the…
-
Submitting a sample: the process end to end Replied, post #58 · Sourcing › Independent verification · 4 Jul 2026 · 29 likes This follows post #55 rather than contradicting it. It does not extend to lots nobody has seen, it is not a recommendation, and it says nothing about anything other…
-
NHS criteria and how they are applied in practice Replied, post #8 · Regional › UK & Ireland · 21 Jun 2026 · 2 likes Post #7 is right about the mechanism and I think understates the practical bit. Members outside these two jurisdictions reading this thread should note that none of it…
-
Racemisation and why it is invisible to a mass measurement Replied, post #123 · Analytics › Impurities & related substances · 15 Jun 2026 · 0 likes Incomplete deprotection leaves a protecting group attached, raising the mass substantially and usually pushing retention much later. A late-eluting peak on a peptide…
-
Fixed versus detachable needles: the trade-offs — does this still hold? Replied, post #7 · Devices › Syringes & needles · 13 Jun 2026 · 0 likes I read post #5 twice before replying, because I had assumed the opposite. Gauge is the outside diameter and higher numbers are thinner. Thinner needles hurt less and…